# A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

> **NCT06161571** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Akero Therapeutics, Inc** · enrollment: 700 (estimated)

## Conditions studied

- NASH/MASH
- NAFLD/MASLD

## Interventions

- **DRUG:** Efruxifermin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06161571
- **Lead sponsor:** Akero Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-11-10
- **Primary completion:** 2026-03-03
- **Final completion:** 2026-06-19
- **Target enrollment:** 700 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06161571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06161571, "A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06161571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*